Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors

Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors

BackgroundFront-line therapy with an EGFR tyrosine kinase inhibitor (TKI) is the standard of care for treating patients with advanced nonsquamous NSCLC with the common sensitizing EGFR exon 19 deletion and exon 21 L858R point mutations. However, EGFR TKI resistance inevitably develops. The optimal s...

Full description

Bibliographic Details
Main Authors: Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
advanced non-small cell lung cancer
sensitizing EGFR mutation
overall survival
platinum-containing chemotherapy
subsequent therapy
tyrosine kinase inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1285280/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1285280/full

Similar Items